Showing results (61-70 of 128) with videos related to
Sort By:
Pageof 13
International Journal of Cancer|February 1, 2014
Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomicsDaniel S W Tan, Sophie Camilleri-Broët, Eng Huat Tan, et al.The Lancet. Respiratory Medicine|January 20, 2020
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 studyDaniel S-W Tan, Natasha B Leighl, Gregory J Riely, et al.Molecular Cancer|January 28, 2014
Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancerDaniel S W Tan, Benjamin Haaland, Jia Min Gan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2024
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001Lori J Wirth, Marcia S Brose, Vivek Subbiah, et al.Lung Cancer (Amsterdam, Netherlands)|May 19, 2024
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancerEnriqueta Felip, Giulio Metro, Daniel S W Tan, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 11, 2021
Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLCJoe Yeong, Lisda Suteja, Yannick Simoni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2018
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung CancerYi-Long Wu, Li Zhang, Dong-Wan Kim, et al.Clinical Lung Cancer|June 29, 2025
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation StatusLyudmila Bazhenova, J G Hodgson, D Ross Camidge, et al.Cancer Research Communications|March 21, 2025
The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N TrialsBenjamin J Solomon, Daniel S W Tan, Gilberto de Castro, et al.Human Genomics|July 17, 2023
Landscape of germline pathogenic variants in patients with dual primary breast and lung cancerNing-Yuan Lee, Melissa Hum, Sabna Zihara, et al.Pageof 13